This post is drawn from a BMJ
review which is one of the best I've seen on the topic. Though
titled Management of interstitial lung disease associated with connective tissue disease it
covers both treatment and diagnosis of the entire spectrum of
pulmonary manifestations. Some key points are discussed below.
Systemic
sclerosis
Interstitial lung disease (ILD) exists in most patients at some point
in the course with a wide spectrum of severity. Pulmonary
hypertension (PH) is common but less so. ILD tends to associate more
with the diffuse form of SScl and PH with the limited form but the
associations are not exclusive and both can occur at the same time.
Nonspecific interstitial pnuemonitis (NSIP) is the most common
histologic pattern but usual interstitial pneumonitis (UIP) is seen
in 10-20%. Though steroids are commonly used as initial treatment
across the spectrum of CTD associated ILD of a variety of causes,
caution is in order with SScl due to the association of steroid use
with an increased risk of renal crisis. Dosage limitations apply.
Pleural involvement is unusual.
Rheumatoid
arthritis
ILD is common with UIP in half or more. Airway and pleural disease
are common. PH is unusual.
Sjogren's
syndrome
ILD is less common than in many other rheumatic diseases but does
sometimes occur in the form of NSIP and lymphocytic interstitial
pneumonitis (LIP).
Mixed
connective tissue disease
This was described in the 1970's as a distinct entity. Though there
has been some controversy about whether it is a variant of, or
overlap with other CTDs clarity is best served by considering it a
separate disease defined by positivity to anti-U1 RNP. ILD is common
and in the form if NSIP. PH is characteristic and a patient can have
both PH and ILD. Airway disease occurs occasionally in the form of
bronchiolitis obliterans (BO). Pleural (and pericardial) involvement
are common.
Polymyositis
and dermatomyositis
ILD
is common though PH is not. The relationship between inflammatory
myopathy, ILD, other pulmonary problems and various serologic
patterns is complex. I discussed some of those relationships in an
earlier post.
Since that post, a syndrome of antibody to MDA-5
has emerged as an aggressive form of ILD associated with inflammatory
myopathy. ILD may arise as the first manifestation of inflammatory
myopathy, lacking findings of associated myositis.
Systemic
lupus erythematosis
In lupus, ILD is less characteristic than a number of other pulmonary
manifestations. Reports of ILD in lupus may in some cases actually
represent MCTD. Pleural (and pericardial) involvement are more
prominent. Also well known are presentations resembling acute
pneumonitis: lupus pneumonitis, diffuse alveolar hemorrhage and
infection. PH due to SLE per se is not characteristic but pulmonary
vascular disease in the form of VTE may occur in patients at special
risk (eg those with accompanying antiphospholipid syndrome). Finally
shrinking lung syndrome (NOT to be confused with vanishing lung
syndrome) is a condition of hypoinflation of poorly understood
pathophysiology, unknown whether neuropathic, myopathic or both.
I
have previously posted on this general topic here.
No comments:
Post a Comment